RedHill Biopharma Ltd. has announced a significant development in its operations by regaining the ex-North America rights to RHB-102. This decision comes through a mutual agreement with Hyloris Pharmaceuticals SA, which effectively terminates their previous License & Development Agreement. The change is crucial for RedHill as it seeks to enhance its control over RHB-102's development and potential market reach.
RHB-102 is a proprietary, bimodal extended-release oral tablet formulation of ondansetron, which is primarily used as a 5-HT3 antagonist. The termination of the License Agreement, which was originally dated February 24, 2025, was finalized on October 15, 2026. As part of this agreement, Hyloris will pay RedHill a one-time break-up fee of $200,000.
With the return of all ex-North America rights, RedHill is now positioned to continue its late-stage development of RHB-102 for oncology support and gastrointestinal indications, including GLP-1/GIP-associated GI intolerance. The company is also exploring potential partnerships to further advance the drug's development.
RedHill Biopharma Ltd. operates under the SIC classification of Pharmaceutical Preparations, which includes companies engaged in the research, development, and manufacturing of drugs and pharmaceutical products. This strategic move not only strengthens RedHill's portfolio but also highlights the competitive landscape within the pharmaceutical industry.
Looking ahead, RedHill's next steps are not detailed in the filing. However, the company’s regained rights to RHB-102 could lead to new opportunities for collaboration and partnership in the pharmaceutical market.